Forte Biosciences Inc
F:37T
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Forte Biosciences Inc
F:37T
|
US |
|
A
|
Amgen Inc
DUS:AMG
|
US |
|
Zai Lab Ltd
F:1ZLB
|
CN |
|
H
|
Hangzhou Greatstar Industrial Co Ltd
SZSE:002444
|
CN |
Forte Biosciences Inc
Forte Biosciences is a clinical-stage biopharmaceutical company that develops drug candidates for immune-driven and inflammatory diseases, especially conditions affecting the skin and other autoimmune disorders. It does not sell approved medicines today. Its work is to discover, test, and advance new therapies through the clinical trial process until they are ready for regulators and, if successful, for doctors and patients to use. Because it is still in development, Forte does not have a traditional customer base like a consumer company. Its main end users would be patients treated by physicians, usually through hospitals, clinics, and specialty doctors. The company makes money in the biotech way: by raising capital to fund research, and potentially in the future through partnerships, licensing deals, or sales of approved drugs if its candidates reach the market. What makes Forte’s business model different is that it is a focused drug developer, not a broad pharmaceutical seller. Its value comes from building a small number of proprietary drug programs and proving they can work and be safe in human studies. In simple terms, Forte is trying to turn scientific research into a prescription medicine business, with most of the risk and reward tied to clinical trial results and regulatory approval.
Forte Biosciences is a clinical-stage biopharmaceutical company that develops drug candidates for immune-driven and inflammatory diseases, especially conditions affecting the skin and other autoimmune disorders. It does not sell approved medicines today. Its work is to discover, test, and advance new therapies through the clinical trial process until they are ready for regulators and, if successful, for doctors and patients to use.
Because it is still in development, Forte does not have a traditional customer base like a consumer company. Its main end users would be patients treated by physicians, usually through hospitals, clinics, and specialty doctors. The company makes money in the biotech way: by raising capital to fund research, and potentially in the future through partnerships, licensing deals, or sales of approved drugs if its candidates reach the market.
What makes Forte’s business model different is that it is a focused drug developer, not a broad pharmaceutical seller. Its value comes from building a small number of proprietary drug programs and proving they can work and be safe in human studies. In simple terms, Forte is trying to turn scientific research into a prescription medicine business, with most of the risk and reward tied to clinical trial results and regulatory approval.
Cash runway: Forte ended the quarter with approximately $54.8 million in cash and cash equivalents and said that should fund operations for at least the next 12 months.
Study update: The company completed enrollment in its randomized controlled phase 2 trial of FB-401, with 154 subjects versus an original target of 124.
Data timing: Management expects to report phase 2 results in the third quarter.
Safety and use: Executives said the spray formulation appears straightforward to use, with no meaningful compliance issues seen so far, including in younger children.
IP progress: Forte said it received two additional patents, bringing its U.S. patent count to 11, with more filings moving forward outside the U.S.
Regulatory path: Management said the FDA review is being handled through the division of vaccines and related products, with dermatology input, and that European and Asia development plans are being explored.
